Form D · Biotechnology
Protagenic Therapeutics Inc.
New York, NY · CIK 0001383099
Offering snapshot reported Sep 27, 2013 · SEC filing
- Reported sold
- $643K Offering amount: $643K
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 15, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 27, 2013 | Initial | $642,789 | No comparison | 5 | SEC filing |
| Feb 2, 2012 | Initial | $375,000 | No comparison | 5 | SEC filing |
| Nov 13, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Sep 5, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 24, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-203658
Source: Form D, filed Sep 27, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Garo Armen | Director |
| Khalil Barrage | Director |
| Hartoun Hartounian | Director |
| Robert Ziroyan | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
149 5 Th Avenue, Suite 500
New York, NY, 10010
New York, NY, 10010